O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+33.09%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$7.07B
AUM Growth
+$7.07B
(+20%)
Cap. Flow
-$90.9M
Cap. Flow
% of AUM
-1.29%
Top 10 Holdings %
Top 10 Hldgs %
31.27%
Holding
162
New
21
Increased
29
Reduced
28
Closed
28
Top Buys
| 1 |
BNR
Burning Rock Biotech
BNR
|
$128M |
| 2 |
Repare Therapeutics
RPTX
|
$106M |
| 3 |
Oric Pharmaceuticals
ORIC
|
$98.6M |
| 4 |
Biogen
BIIB
|
$63M |
| 5 |
Keros Therapeutics
KROS
|
$63M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$255M |
| 2 |
Gilead Sciences
GILD
|
$98.4M |
| 3 |
Pfizer
PFE
|
$98.3M |
| 4 |
HCA Healthcare
HCA
|
$63.8M |
| 5 |
Stryker
SYK
|
$61.8M |
Sector Composition
| 1 | Healthcare | 97.61% |
| 2 | Financials | 1.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sarepta Therapeutics
SRPT
$1.78B
| $89.7M | 1.26% | 559,649 -342,800 | -38% | -$55M |
|
27
Centene
CNC
$14.3B
| $84.9M | 1.2% | 1,335,700 | – | – |
|
28
Cigna
CI
$80.3B
| $82.5M | 1.16% | 439,700 | – | – |
|
29
89bio
ETNB
$1.34B
| $79.8M | 1.12% | 4,004,442 | – | – |
|
30
Enliven Therapeutics
ELVN
$1.2B
| $75.2M | 1.06% | 2,719,902 | – | – |
|
31
Adverum Biotechnologies
ADVM
$64.6M
| $68.7M | 0.97% | 3,290,744 -159,900 | -5% | -$3.34M |
|
|
DCPH
32
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $67.2M | 0.95% | 1,125,700 -31,900 | -3% | -$1.91M |
|
33
Intuitive Surgical
ISRG
$170B
| $64.3M | 0.9% | 112,800 -56,300 | -33% | -$32.1M |
|
|
34
Keros Therapeutics
KROS
$618M
| $63M | 0.89% | +1,679,417 | New | +$63M |
|
35
eHealth
EHTH
$118M
| $62.7M | 0.88% | 638,558 | – | – |
|
36
NextCure
NXTC
$13.5M
| $58.1M | 0.82% | 2,711,013 | – | – |
|
37
Exelixis
EXEL
$10.1B
| $57.1M | 0.8% | 2,404,100 -776,000 | -24% | -$18.4M |
|
38
KALA BIO
KALA
$78.8M
| $56.8M | 0.8% | 5,402,730 | – | – |
|
|
FUSN
39
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $56.3M | 0.79% | +3,224,770 | New | +$56.3M |
|
40
AtriCure
ATRC
$1.84B
| $55.2M | 0.78% | 1,228,189 +300,000 | +32% | +$13.5M |
|
|
ATNX
41
DELISTED
Athenex, Inc. Common Stock
ATNX
| $55.2M | 0.78% | 4,009,346 | – | – |
|
|
LOGC
42
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
| $54.7M | 0.77% | 6,466,783 | – | – |
|
43
Theravance Biopharma
TBPH
$699M
| $53.6M | 0.75% | 2,554,470 +2,342,925 | +1,108% | +$49.2M |
|
|
BLU
44
DELISTED
BELLUS Health Inc.
BLU
| $53M | 0.75% | 5,137,216 -1,888,616 | -27% | -$19.5M |
|
45
CRISPR Therapeutics
CRSP
$4.71B
| $51.3M | 0.72% | 697,524 +146,324 | +27% | +$10.8M |
|
46
Crinetics Pharmaceuticals
CRNX
$2.92B
| $48.2M | 0.68% | 2,753,567 +714,285 | +35% | +$12.5M |
|
47
Glaukos
GKOS
$5.5B
| $46.5M | 0.66% | 1,211,000 -336,646 | -22% | -$12.9M |
|
48
MeiraGTx Holdings
MGTX
$587M
| $46.5M | 0.65% | 3,713,820 +131,500 | +4% | +$1.65M |
|
49
AbbVie
ABBV
$372B
| $45.6M | 0.64% | 464,000 +235,000 | +103% | +$23.1M |
|
50
Mersana Therapeutics
MRSN
$36.5M
| $44.7M | 0.63% | 1,910,008 +563,287 | +42% | +$13.2M |
|